Prostate Cancer
Stay at the forefront of prostate cancer care with insights from the Lancet, featuring groundbreaking research and authoritative reviews that inform the latest advances in diagnosis, treatment, and patient care.
Research in Context
Research in Context is a structured summary that editors at The Lancet’s journals ask all authors to provide when submitting an original research article. Read more
Featured Article
On-treatment PSA linked to long-term survival in prostate cancer, post-hoc analysis finds
Researchers reported that PSA values, combined with metastatic volume or nodal status, improved estimation of 8-year survival, with prospective evaluation needed before any use in treatment personalization.
The Lancet Group reaches millions of clinicians and researchers worldwide.
ARANOTE: darolutamide plus ADT linked with delayed pain and wellbeing decline vs placebo in mHSPC
In an exploratory subgroup analysis, investigators reported the greatest pain and HRQoL benefits among patients with deep PSA responses in this phase 3 trial.
Randomised phase 2 BULLSEYE trial: ¹⁷⁷Lu-PSMA-617 in oligometastatic HSPC
Long-term outcomes and delayed toxic effects remain under investigation, but investigators report the trial suggests ¹⁷⁷Lu-PSMA-617 could delay disease progression in high-risk oligometastatic hormone-sensitive prostate cancer.
[177Lu]Lu-PSMA-617 plus immune checkpoint inhibition in mCRPC
Researchers reported the first study of multiple-cycle combination therapy, with PSA responses and disease control observed in a subset of men with metastatic castration-resistant prostate cancer and a manageable adverse event profile.
PSMA-PET PPP3 nomograms for prostate cancer survival risk assessment
An international, retrospective, registry-based study reports externally validated PPP3 nomograms for 3-, 5-, and 7-year overall survival, with superior prediction accuracy versus NCCN risk scores and, in specific subgroups, versus EAU and GAFITA scores.
Cohort-derived nomogram, externally validated, estimates ADT-free survival after MDT in PSMA PET–staged prostate cancer
Developed in a multicentric cohort of 586 patients and externally validated in 131 independent patients, the model stratifies men with metachronous oligometastatic prostate cancer treated with MDT into risk groups for 1- and 2-year ADT-free survival.
Seven-fraction ultra-hypofractionation in intermediate-risk localised prostate cancer
Ten-year follow-up from the Scandinavian HYPO-RT-PC randomised trial reported non-inferior failure-free survival versus conventional fractionation, with similar long-term toxicity; no patients received androgen deprivation therapy.
WOLVERINE meta-analysis: MDT linked to progression benefits, not survival gain, in oligometastatic prostate cancer
An individual patient meta-analysis found that although overall survival did not meet significance criteria, MDT plus SOC was associated with benefits across several progression-related endpoints versus SOC.
Abemaciclib plus abiraterone did not improve outcomes in mCRPC, authors report
In this randomised, placebo-controlled study, adding a CDK4/6 inhibitor did not improve outcomes in mCRPC; the authors say further research is needed on possible subgroup benefit.
TALAPRO-2 phase 3 trial reports overall survival benefit in HRR-altered metastatic prostate cancer
In a prespecified secondary-endpoint analysis, talazoparib plus enzalutamide was associated with improved overall survival versus enzalutamide plus placebo in patients with metastatic castration-resistant prostate cancer and prospectively assessed tumour HRR gene alterations; subgroup findings are exploratory.